If you have a friend or loved one who is battling Alzheimer’s disease, you know just how cruel the illness can be. Today, more than 5 million Americans are living with Alzheimer’s, and its rate of diagnosis is increasing as the baby boomer generation ages. Sadly, there is no cure for the disease and no treatments are effective in slowing its progression. But there is hope.
Recently, the BroadMinded blog highlighted the exciting science emerging from the Roadmap Epigenomics program, resulting in the most comprehensive map of the human epigenome — the collection of chemical changes to DNA and its supporting proteins that help control how genes are turned on or off.
The American Academy of Neurology and the American Brain Foundation are awarding the 2015 Potamkin Prize for Research in Pick's, Alzheimer's and Related Diseases to Peter Davies, PhD, of the Feinstein Institute for Medical Research in Manhasset, NY, and Reisa A. Sperling, MD, of the Brigham and Women's Hospital and Massachusetts General Hospital in Boston.
The ability to recall names and faces with lightning speed may start to fade in one’s 20s, but our capability to perform other functions, such as learning new words, doesn’t peak until decades later, according to a new study by Boston scientists.
A National Institutes of Health-led public-private partnership to transform and accelerate drug development achieved a significant milestone today with the launch of a new Alzheimer’s Big Data portal - including delivery of the first wave of data - for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, the U.S.
Alzheimer's researchers at Harvard for the first time are scanning the brains of healthy patients for the presence of a hallmark protein called tau, which forms toxic tangles of nerve fibers associated with the fatal disease.
The new scans are part of a large clinical trial called Anti-Amyloid Treatment in Asymptomatic Alzheimer's or A4, the first designed to identify and treat patients in the earliest stages of Alzheimer's, before memory loss begins.
Venture capitalists are known for making bold bets on high-risk projects that have the potential for huge payoffs. Today, driven by that vision, a group of business leaders who founded the Cure Alzheimer’s Fund (CAF) to find a cure for this disease are seeing important returns on their investment in research at Mass General and beyond.
The scientific results the CAF support has brought about are nothing short of game changing as Mass General researchers resolve some long-unanswered questions about how Alzheimer’s disease develops.
Although natural selection is often thought of as a force that determines the adaptation of replicating organisms to their environment, Harvard researchers have found that selection also occurs at the level of neurons, which are post-mitotic cells, and plays a critical role in the emergence of Alzheimer’s disease.
Banked brain tissue enables crucial advances in the understanding and treatment of degenerative disorders. As appreciation of the many different variants of neurodegenerative disease is growing, well-preserved tissue is in more demand than ever. Are the brain banks up to the task? Modern banks are harmonizing protocols, combining their inventories in online listings, and maintaining databases of detailed longitudinal data. At the same time, these institutions face funding shortfalls that threaten continued progress.
Our susceptibility to disease depends both on the genes that we inherit from our parents and on our lifetime experiences. These two components - nature and nurture - seem to affect very different processes in the context of Alzheimer's disease, according to a new study published today in the journal Nature.